Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,683.00+3.69%ETH$2,436.19+6.33%GOLD$4,072.20-0.02%OIL$88.04-0.09%
Smart Investors Daily
SID Premium
TO

AMEX · TOVX

Theriva Biologics, Inc.

Healthcare · Biotechnology

$0.18

Up+$0.01 (+4.40%)

Updated Nov 4, 2026, 11:01 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
7.76M
P/E ratio
-0.05
Dividend yield
0.00%
52-week range
$0.14 – $0.49
Volume
2.38M
Avg. volume
15.36M

Price performance · TOVX

TOVX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

TOVX closed at $0.18 after 21 trading sessions, down 18.02% for the selected period.

Last close
$0.18
Period change
-18.02%
Period low
$0.17
Period high
$0.23
Daily close
View OHLC price history
TOVX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$0.185$0.2016$0.1775$0.1822.38M
Nov 2, 2026$0.15$0.1907$0.1361$0.18491.36M
Oct 30, 2026$0.187$0.1876$0.1668$0.17051.44M
Oct 29, 2026$0.1866$0.1896$0.1849$0.187444.06K
Oct 28, 2026$0.187$0.191$0.1839$0.1899253.36K
Oct 27, 2026$0.1934$0.1953$0.1838$0.188549.63K
Oct 26, 2026$0.191$0.1956$0.19$0.1934410.59K
Oct 23, 2026$0.19$0.20$0.19$0.196429.87K
Oct 22, 2026$0.20$0.2035$0.19$0.19589.1K
Oct 21, 2026$0.2097$0.217$0.1966$0.1966751.28K
Oct 20, 2026$0.209$0.214$0.204$0.208331.5K
Oct 19, 2026$0.208$0.21$0.2047$0.2047237.3K
Oct 16, 2026$0.2165$0.2165$0.2077$0.2079251K
Oct 15, 2026$0.2114$0.221$0.2096$0.212364.4K
Oct 14, 2026$0.2159$0.2234$0.2097$0.2099381.99K
Oct 13, 2026$0.224$0.2249$0.2149$0.2157360.16K
Oct 12, 2026$0.22$0.2362$0.2101$0.21941.62M
Oct 9, 2026$0.2263$0.2329$0.212$0.217488.34K
Oct 8, 2026$0.234$0.237$0.2271$0.2271526.78K
Oct 7, 2026$0.2267$0.2468$0.224$0.234808.29K
Oct 6, 2026$0.2255$0.2366$0.22$0.222407.43K

Latest TOVX news

The latest Smart Investors Daily articles mentioning TOVX.

Stock researchCompany · Overview

TOVX research

Overview

Company profile and research snapshot.

Company profile

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.14
Implied upside
—
Analysts
8
TOVX recent ratings
DateFirmRatingTarget
Mar 31, 2026Maxim GroupBuy—
May 8, 2025Maxim GroupHold—
Nov 13, 2024Maxim GroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine

- Publication in this premier journal after rigorous peer review validates the VIRAGE study and supports the continued evaluation of VCN-01 in the treatment of metastatic pancreatic cancer - - Data are consistent with an immune mediated mechanism of action for VCN-01 that may enhance the antitumor effects of a range of coadministered pancreatic cancer therapies - - The feasibility of administering more frequent repeated VCN-01 doses to potentially improve clinical outcomes in metastatic pancreat

Benzinga · Aug 11, 2026

Theriva Biologics Q2 EPS $(0.07) Misses $(0.05) Estimate

Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 96.37 percent increase over losses of $(1.93) per share from

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By